Sam Alexander Martino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sam Alexander Martino has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Dénes Berta
Budapest University of Technology and Economics
3 shared publications - Andrei V. Pisliakov
Computational Biology, School of Life Sciences, University of Dundee
2 shared publications - Edina Rosta
Department of Physics and Astronomy, University College London, London, UK
2 shared publications - Elisa Frezza
Université Paris Cité, CiTCoM, CNRS
2 shared publications - Magd Badaoui
University College London, Department of Physics and Astronomy
2 shared publications - Nadia Elghobashi-Meinhardt
School of Chemistry, University College Dublin
2 shared publications
Latest Publications
- 2 October 2023
- Published by Taylor & Francis in Crystallography Reviews
- Vol. 29 (4) , 202-227
What a twist: structural biology of the SARS-CoV-2 helicase nsp13
- 2 October 2023
- Published by Taylor & Francis in Crystallography Reviews
- Vol. 29 (4) , 202-227
What a twist: structural biology of the SARS-CoV-2 helicase nsp13
- Open Access
- 6 September 2021
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 12 (40) , 13492-13505
Modelling the active SARS-CoV-2 helicase complex as a basis for structure-based inhibitor design
The RNA helicase (non-structural protein 13, NSP13) of SARS-CoV-2 is essential for viral replication, and it is highly conserved among the coronaviridae family, thus a prominent drug target to treat COVID-19.
- 6 September 2021
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 12 (40) , 13492-13505
Open AccessModelling the active SARS-CoV-2 helicase complex as a basis for structure-based inhibitor design
The RNA helicase (non-structural protein 13, NSP13) of SARS-CoV-2 is essential for viral replication, and it is highly conserved among the coronaviridae family, thus a prominent drug target to treat COVID-19.
- Open Access
Modelling the active SARS-CoV-2 helicase complex as a basis for structure-based inhibitor design
Having claimed over 1 million lives worldwide to date, the ongoing COVID-19 pandemic has created one of the biggest challenges to develop an effective drug to treat infected patients. Among all the proteins expressed by the virus, RNA helicase is a fundamental protein for viral replication, and it is highly conserved among the coronaviridae family. To date, there is no high-resolution structure of helicase bound with ATP and RNA. We present here structural insights and molecular dynamics (MD) simulation results of the SARS-CoV-2 RNA helicase both in its apo form and in complex with its natural substrates. Our structural information of the catalytically competent helicase complex provides valuable insights for the mechanism and function of this enzyme at the atomic level, a key to develop specific inhibitors for this potential COVID-19 drug target.
Open AccessModelling the active SARS-CoV-2 helicase complex as a basis for structure-based inhibitor design
Having claimed over 1 million lives worldwide to date, the ongoing COVID-19 pandemic has created one of the biggest challenges to develop an effective drug to treat infected patients. Among all the proteins expressed by the virus, RNA helicase is a fundamental protein for viral replication, and it is highly conserved among the coronaviridae family. To date, there is no high-resolution structure of helicase bound with ATP and RNA. We present here structural insights and molecular dynamics (MD) simulation results of the SARS-CoV-2 RNA helicase both in its apo form and in complex with its natural substrates. Our structural information of the catalytically competent helicase complex provides valuable insights for the mechanism and function of this enzyme at the atomic level, a key to develop specific inhibitors for this potential COVID-19 drug target.